IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 12-Month Low – What’s Next?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $26.56 and last traded at $26.9810, with a volume of 72,622 shares trading hands. The stock had previously closed at $27.40.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wall Street Zen downgraded IDEAYA Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Wedbush boosted their target price on IDEAYA Biosciences from $60.00 to $63.00 and gave the company an “outperform” rating in a research note on Wednesday, November 4th. William Blair assumed coverage on IDEAYA Biosciences in a report on Friday, October 16th. They set an “outperform” rating for the company. Stifel Nicolaus initiated coverage on IDEAYA Biosciences in a research report on Wednesday, October 14th. They set a “buy” rating and a $48.00 price target on the stock. Finally, Citigroup lifted their price target on IDEAYA Biosciences from $65.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $49.55.

View Our Latest Analysis on IDEAYA Biosciences

IDEAYA Biosciences Trading Down 2.5%

The firm has a market cap of $2.58 billion, a P/E ratio of -5.93 and a beta of 0.08. The business’s fifty day simple moving average is $35.05 and its 200-day simple moving average is $33.85.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.04). The firm had revenue of $10.24 million during the quarter, compared to analysts’ expectations of $7.58 million. IDEAYA Biosciences had a negative net margin of 1,157.18% and a negative return on equity of 39.78%. IDEAYA Biosciences’s revenue was up 14.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.33 EPS. Analysts anticipate that IDEAYA Biosciences, Inc. will post -4.63 earnings per share for the current year.

Insider Transactions at IDEAYA Biosciences

In other IDEAYA Biosciences news, CEO Yujiro Hata sold 26,338 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total transaction of $985,304.58. Following the completion of the transaction, the chief executive officer owned 690,695 shares of the company’s stock, valued at $25,838,899.95. This represents a 3.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On IDEAYA Biosciences

Several hedge funds have recently made changes to their positions in the business. Allworth Financial LP lifted its holdings in IDEAYA Biosciences by 95.8% in the third quarter. Allworth Financial LP now owns 883 shares of the company’s stock worth $34,000 after buying an additional 432 shares during the period. Aquatic Capital Management LLC grew its holdings in shares of IDEAYA Biosciences by 3,154.0% during the 3rd quarter. Aquatic Capital Management LLC now owns 45,361 shares of the company’s stock worth $1,743,000 after acquiring an additional 43,967 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of IDEAYA Biosciences by 18.1% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,453,997 shares of the company’s stock worth $55,863,000 after acquiring an additional 222,383 shares during the period. Jump Financial LLC grew its holdings in shares of IDEAYA Biosciences by 326.4% during the 3rd quarter. Jump Financial LLC now owns 239,240 shares of the company’s stock worth $9,192,000 after acquiring an additional 183,131 shares during the period. Finally, Aberdeen Group plc raised its position in shares of IDEAYA Biosciences by 5.3% in the 3rd quarter. Aberdeen Group plc now owns 590,777 shares of the company’s stock worth $22,698,000 after acquiring an additional 29,843 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

(Get Free Report)

IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.

Read More

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.